Privia Health Group, Inc. (PRVA)
OvervaluedFundamental
62
Price
$22.41
Market Cap
$2.87B
Part 1 · What the company is worth
Overview
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$2.36B
Trailing 12 months (through 6/30/2026)
Net Income
$28M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
-
Total Equity
$737M
Total Liabilities
$578M
Current Ratio
1.62
Interest Coverage
-
Debt/EBITDA
0.20
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$18.39
Current Price
$22.41
Margin of Safety
-21.9%
Fair Value Range
$11.95 - $24.83
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
101.86
ROE
3.1%
P/B Ratio
3.66
P/FCF
-
Gross Margin
-
ROIC
4.2%
Profitability Radar
Value Creation (Economic Moat)
ROIC
4.2%
WACC
8.7%
ROIC − WACC
-4.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (12)
- EPS shows upward trend
- EPS CAGR 12.25%
- Debt/equity ratio
- Current ratio
- Debt/EBITDA
- Return on tangible assets
- Revenue growth 5Y 21.0%
- Earnings surprise, average 3.9%
- Earnings quality (operating cash flow / net income) 4.66
- Share dilution -2.6%
- Net margin trend 1.2% vs 0.8%
- Piotroski F-Score 6/9
Failed (8)
- Price CAGR -5.89%
- ROIC 4.2%
- P/B ratio 3.66
- Operating margin 1.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
Unavailable (7)
- Gross margin –
- P/FCF –
- Dividend payout –
- Positive free cash flow
- CapEx intensity
- Interest coverage
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Parth Mehrotra | CEO & Director | 46 |
| Mr. David Mountcastle CPA, MBA | Executive VP & CFO | 55 |
| Mr. Edward Christopher Fargis Esq. | Executive VP, General Counsel, Chief Legal Officer & Corporate Secretary | 60 |
| Mr. Sarath Degala | Chief Operating Officer | - |
| Mr. Konda Mullapudi | Executive VP & CTO | - |
| Mr. Robert P. Borchert | Senior Vice President of Investor Relations & Corporate Communications | - |
| Ms. Dana Fields CPA | Chief Audit & Compliance Officer | - |
| Ms. Jenny Harding | Chief People Officer | - |
| Mr. Jay Stevens | Senior VP & Chief Growth Officer | - |
| Mr. Eric J. Beyer | Executive Vice President of Medical Groups | - |
Audit Risk
1
Board Risk
2
Compensation Risk
3
Shareholder Rights Risk
6
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much PRVA moves, measured on its daily prices.
More volatile than 33% of the tracked stocks (90-day volatility).
- Volatility 30d
- 27.3%
- Volatility 90d
- 29.7%
- Beta vs S&P 500 (1y)
- 0.58Correlation 0.23
- Max drawdown (12m)
- -32.0%
- ATR (14d, % of price)
- 2.75%
Earnings reactions
How PRVA moved around its past quarterly results.
Next earnings release
Nov 5, 2026 · In 12 days · Before the open
EPS estimate: 0.24Revenue estimate: $611M
What usually happens
- Over the last 12 releases the stock moved a median of 6.2% the next day, up or down.
- Next-day moves: up 7, down 4 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | During the session | 0.07 | 0.07 | +2.3% | -12.8% | -8.2% | -10.1% |
| May 7, 2026 | During the session | 0.08 | 0.02 | -73.7% | -4.3% | 0.0% | -5.7% |
| Feb 26, 2026 | During the session | 0.04 | 0.07 | +96.1% | +1.7% | +10.0% | +7.3% |
| Nov 6, 2025 | During the session | 0.05 | 0.05 | -8.9% | +5.8% | -4.2% | -3.2% |
| Aug 7, 2025 | During the session | n/a | n/a | n/a | +1.1% | -1.4% | +6.3% |
| May 8, 2025 | During the session | n/a | n/a | n/a | +5.1% | +7.5% | +4.2% |
| Feb 27, 2025 | During the session | n/a | n/a | n/a | +1.7% | +5.8% | +6.8% |
| Nov 7, 2024 | During the session | n/a | n/a | n/a | -0.2% | +6.5% | +3.2% |
| Aug 8, 2024 | During the session | n/a | n/a | n/a | +10.0% | +5.9% | +5.5% |
| May 9, 2024 | During the session | n/a | n/a | n/a | -2.0% | -4.4% | -7.9% |
| Feb 27, 2024 | During the session | n/a | n/a | n/a | +4.0% | +9.7% | +9.4% |
| Nov 3, 2023 | During the session | n/a | n/a | n/a | +11.5% | +14.3% | +6.3% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on PRVA and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for PRVA.
- 2/26/2026NEUTRALPrivia Health (PRVA) Q4 2025 Earnings Transcript
The financial market is currently awaiting the detailed transcript of Privia Health's (PRVA) Q4 2025 earnings call. While the specific content remains unavailable, investors will be keenly scrutinizing this document for clarity on the company's financial health and future trajectory. Earnings transcripts are vital as they provide direct insights from management discussions, detailing revenues, profits, operating margins, and crucially, future guidance. The current lack of concrete data keeps the stock in a state of anticipation, with market participants looking for signals regarding patient growth, geographical expansion, and cost management strategies. The stock's reaction will heavily depend on the tone and figures revealed once the full transcript is released.